A Trial of HRS-1893 in Healthy Volunteers

Launched by ATRIDIA PTY LTD. · Jun 13, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new medication called HRS-1893 to understand how it behaves in the body and to make sure it is safe when taken as a single oral dose. Although the study focuses on a heart condition called hypertrophic cardiomyopathy, this particular trial will be done with healthy volunteers to gather early information about the drug.

To take part, volunteers need to be healthy adults between 18 and 55 years old, with specific weight and body mass index (BMI) requirements. Women who could become pregnant must have a negative pregnancy test and agree to use effective birth control, and men must also agree to use birth control methods. People with heart problems, certain allergies, or other health issues will not be eligible. Participants will be asked to follow study procedures carefully and provide consent before joining. This study is not yet recruiting, but when it begins, volunteers can expect to receive one dose of the medication and be monitored to see how their body handles it and ensure it is safe.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Healthy white participants;
• • 2. Ability to understand the trial procedures and possible adverse events, volunteer to participate in the trial, and provide written informed consent, be able to comply with all the requirements, and able to complete the study.
• • 3. Male aged between 18 to 55 years of age (inclusive)
• • 4. Women with body weight ≥ 45.0 kg, men with body weight ≥ 50.0 kg, body mass index (BMI) between 19.0 and 30.0 kg/m2 (inclusive) at screening.
• • 5. Negative pregnancy test for women of childbearing potential (WOCBP) at baseline. Men and WOCBP must agree to take highly effective contraceptive methods
• Exclusion Criteria:
• • 1. History or evidence of clinically significant disorders
• • 2. History of cardiomyopathy and/or unexplained heart failure
• • 3. Individuals with a history of drug allergies, specific allergies
• • 4. Any other circumstances (e.g., not suitable for venous access) or laboratory abnormality that, in the investigator's judgment, may increase the risk to the participant, or be associated with the participant's participation in and completion of the study or could preclude the evaluation of the participant's response.